Target inhibition in glioma cells was confirmed by a FRET-based cAMP assay where RO1 prevented forskolin-stimulated formation by the Grm2/3 agonist LY-379268 (Figure 3A). This evidence concerns the gene GRM2 and central nervous system cancer.